Stocks · News reference

Needham Maintains Buy on Veradermics, Raises Price Target to $164

Jul 15, 2026, 5:10 PMBenzinga Newsdesk

Needham analyst Serge Belanger maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $136 to $164.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 11, 2026, 8:54 PMBenzinga Newsdesk
Veradermics Q2 EPS $(0.58) Beats $(0.65) Estimate
Veradermics (NYSE:MANE) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.65) by 10.77 percent. This is a 97.6 percent increase over losses of $(24.19) per share from the
MANE
SEC EDGARAug 11, 2026, 12:15 PMSEC EDGAR
8-K filing — Veradermics, Inc (MANE)
Filed: 2026-08-11 AccNo: 0001827635-26-000028 Size: 641 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
MANE
BenzingaJul 17, 2026, 5:52 PMBenzinga Newsdesk
Veradermics shares are trading higher after the company announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss.
MANE
BenzingaJul 17, 2026, 11:32 AMBenzinga Newsdesk
Veradermics Presents Data From Phase 2/3 Trial 302 Of VDPHL01 In Male Participants With Mid-To-Moderate Pattern Hair Loss
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the
MANE